Relationship between chronic obstructive pulmonary disease and ischemic heart disease, the place in therapy of calcium anta
Vol 72 No 3 (2016), Therapy
Vol 72 No 3 (2016)

Relationship between chronic obstructive pulmonary disease and ischemic heart disease, the place in therapy of calcium anta

Therapy
Published July 27, 2020
V.N. Pogorelov
Kharkov National Medical University
N.D. Telegina
Kharkov National Medical University
V.V. Brek
Kharkov National Medical University
L.P. Balagova
Kharkov National Medical University
E.P. Maslova
Kharkov National Medical University
K.A. Vasilevskiy
Kharkov National Medical University
PDF (Русский)

Keywords

chronic obstructive pulmonary disease ischemic heart disease
pulmonary hypertension
diltiazem
amlodipine

How to Cite

Pogorelov, V., Telegina, N., Brek, B., Balagova, L., Maslova, E., & K.A. Vasilevskiy, K. (2020). Relationship between chronic obstructive pulmonary disease and ischemic heart disease, the place in therapy of calcium anta. Experimental and Clinical Medicine, 72(3), 64-68. Retrieved from https://ecm.knmu.edu.ua/article/view/521
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

In 50 patients with chronic obstructive pulmonary disease in combination with ischemic heart disease treated in a comprehensive therapy diltiazem (comparison group) and amlodipine (main group), studied indexes of pulmonary hemodynam-ics, the renin-angiotensin system, endothelin-1, immuno-inflammatory process and lipid metabolism. Comparative statistical analysis showed that patients the main group noted a significant decrease of renin, angiotensin II, endothelin-1, li-pid profile and proinflammatory cytokines, as well as saw stable antihyperten-sive and antiischemic effects than in the comparison group.
PDF (Русский)

References

Латогуз І.К. Особливості, механізми та чинники синдрому взаємного ускладнення, що обумовлюють кардіопульмональну патологію / І.К. Лато-гуз, В.М. Погорєлов, В.І. Жуков // Буковинський медичний вісник. – 2003. – Т. 7, № 2. – С.157–163.

Погорєлов В.М. Місце ішемічної хвороби серця у хворих на хронічне обструктивне захворювання легенів та аспекти лікування синдрому «Обопі-льного обтяження» / В.М. Погорєлов, В.В. Брикалін, С.В. Денисова // Вест-ник гигиены и эпидемиологии. – 2010. – Т. 14, № 2. – С. 260–264.

Golgsmith S.R. Effect of amlodipine and felodipine on sympathetic activity and baroreflex function in normal humans / S.R. Golgsmith // Am J Hypertens. – 1995. – Vol. 8, № 9. – Р. 902–908.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial / S. Jul-ius, S.E. Kjeldsen, M. Weber et al. // Lancet. – 2004. – Vol. 363. – Р. 2022–2031.

Deanfield J. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial) / J. Deanfield, J.M. Detry, P.R. Lichtlen // Am. J. Coll Car-diol. – 1994. – Vol. 24. – Р. 1460–1467.

Safety of long-acting dihydropyridine calcium channel blockers in hyperten-sive patients / R.A. Kloner, G.W. Vetrovec, B.J. Materson, M. Levenstein // Am. J. Cardiol. – 1998. – Vol. 81, № 2. – Р. 163–169.

Погорелов В.Н. Влияние комбинированной терапии антагонистов каль-ция на гемодинамику больных хроническим легочным сердцем / В.Н. Пого-релов, И.К. Латогуз, О.Д. Кучеренко // Врачебная практика: ХГМУ. – 2000. – № 5. – С. 73–77.

Карпов Ю.А. Фармакотерапия в кардиологии: позиции антагонистов кальция / Ю.А. Карпов, Е.В. Сорокин // Consilium Medicum. – 2004. – № 6. – С. 5.

The relationship between magnitude of proteinuria reduction and risk of end–stage renal disease: results of the African American study of kidney disease and hypertension / J. Lea, T. Green, L. Hebert et al. // Arch. Intern. Med. – 2005. – Vol. 165, № 8. – Р. 947–953.

Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma / D.O. Williams, P.J. Barnes, H.P. Vickers et al. // BMJ. – 1981. – Vol. 282. – Р. 348.

Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension / H. Chen, T. De Marco, E.A. Kobashigawa et al. // Eur. Respir. J. – 2011. – Vol. 38, № 3. – P. 608–616.